Congo
Tuberculosis profile
| High HIV burden |
Population  2012 4.3 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.8 (0.78–3.4) 42 (18–77)
Mortality (HIV+TB only) 1 (0.82–1.2) 24 (19–27)
Prevalence  (includes HIV+TB) 23 (11–40) 530 (250–913)
Incidence  (includes HIV+TB) 17 (14–20) 381 (311–458)
Incidence (HIV+TB only) 3.6 (2.9–4.3) 83 (68–100)
Case detection, all forms (%) 68 (57–84)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 984 (36) Relapse 272 (57)
Smear-negative 3 937 (36) Treatment after failure 117 (24)
Smear-unknown / not done 0 (0) Treatment after default 92 (19)
Extrapulmonary 3 110 (28) Other 0 (0)
Other 0 (0)      
Total new 11 031   Total retreatment 481  
           
Other (history unknown) 0        
Total new and relapse 11 303   Total cases notified 11 512  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.4    
Age < 15 109 480  
Laboratories 2012
Smear (per 100 000 population) 0.8
Culture (per 5 million population)  
Drug susceptibility testing (per 5 million population)  
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 71   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment 51  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 979 (17)
HIV-positive TB patients 653 (33)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 132 (20)
HIV-positive TB patients on antiretroviral therapy (ART) 152 (23)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.5 (0.01–5) 10 (3.5–17)
MDR-TB cases among notified pulmonary
TB cases
200 (1–400) 49 (17–81)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases      
Patients started on MDR-TB treatment      
Financing TB control 2013
National TB programme budget (US$ millions) 1.8
% Funded domestically 59%
% Funded internationally 41%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data